Spiriva is now the preferred drug to treat bronchospasm caused by chronic obstructive pulmonary disease (COPD) for ConnectiCare commercial members.
Starting Oct. 1, 2019, Tudorza Pressair will be moved to a non-preferred tier on the commercial plan formularies. This means commercial members who continue to take this drug after Oct. 1 may pay higher copayments or coinsurance. We have sent letters to patients who are affected by this.
If you want to keep your commercial patient on Tudorza Pressair after Oct. 1, submit a preauthorization request before prescribing the medication. Fax the preauthorization request to us at 1-800-249-1367.
Please note, the preauthorization requirement does not apply to patients with employer-sponsored plans through municipal governments.
